EventsThe 5th International Electronic Conference on Cancers
Published
This submission belongs to the session S3. Drug Resistance and Anti-cancer Drug Development and Screening of the event The 5th International Electronic Conference on Cancers
Published date
05 Jun, 2026
Academic Editor
author-avatarFarrukh Aqil
Citation
Zain Nofal, Margarita Pustovalova, Sergey Leonov, Confined migration-derived breast cancer sublines reveal subtype‑specific responses to Arp2/3 inhibition, in Proceedings of The 5th International Electronic Conference on Cancers, 10 June–12 June 2026, MDPI: Basel, Switzerland
Share
Email
Facebook
Twitter
LinkedIn

Confined migration-derived breast cancer sublines reveal subtype‑specific responses to Arp2/3 inhibition

image
1. Institute of Future Biophysics, Moscow Center for Advanced Studies, 123592 Moscow, Russia, Russia
2. Institute of Future Biophysics, Moscow Institute of Physics and Technology (University) 141701 Dolgoprudny, Russia, Russia
Abstract

Introduction: Cancer cell migration through confined tissue spaces (CM) leads to the development of a pro-migratory phenotype. The Arp2/3 complex aids in cell movement, creating branched actin networks, and can be blocked by CK-666. We examined how CM‑derived sublines of low‑metastatic MCF7 and high‑metastatic MDA‑MB‑231 change their mechanics, proliferation, and collective migration in response to CK‑666.

Methods: Parental and CM sublines of MDA-MB-231 and MCF7 were generated by three rounds of CM through 8 μm pores. Young’s modulus was measured by scanning ion-conductance microscopy. Proliferation, fraction of DNA-replicating cells and collective migration weredetected by SRB, Ki67 immunofluorescence and wound healing assays, respectively, at 24 h after treatment.

Results: CM-derived MDA-MB-231 and MCF7 sublines were significantly softer compared to parental counterparts (1051 ± 624.2 vs. 786.4 ± 531 Pa and 2446 ± 1391 vs. 1614 ± 1198 Pa, respectively, all p < 0.05). CM-derived MCF7 cells showed 17.5% (p = 0.0097) increased viability relative to parental cells after CK-666 treatment, while MDA-MB-231 cells remained unaffected. CK-666 treatment reduced DNA-replicating fraction in MDA-MB-231 CM cells to 23.0 ± 2.4% (p = 0.0018) vs. 39.9 ± 1.54% in controls. No significant change was observed in parental cells or in MCF7 cells. CK-666 markedly decreased the migration of parental MDA-MB-231 cells (17.8 ± 5.25% vs. 34.3 ± 6.3% ) and stopped the migration of CM MDA-MB-231 cells (no closure vs. 25.4 ± 11.0% in controls). CK-666 treatment also diminished collective migration of parental MCF-7 cells (5.28 ± 3.8% vs. control 18.3 ± 1.1%), while CM MCF7 cells retained substantial wound closure (10.9 ± 1.37% vs. control 22.9 ± 3.2%).

Conclusions: CM‑related softening is accompanied by subtype‑specific functional responses to Arp2/3 inhibition. In high‑metastatic MDA‑MB‑231, CM and Arp2/3 blockade together shift cells into a viable but low‑proliferation, migration‑defective state. In contrast, in low‑metastatic MCF7, the softened CM subline preserves higher proliferation and substantial motility under CK‑666, suggesting more Arp2/3‑independent, mechanically adapted migration and a more drug‑tolerant phenotype.

Keywords
Confined migration
Arp2/3
CK‑666
Breast cancer
Oral Presentation
Poster
poster nofal.pdf
Enhancing Analytical Rigor: A pathologist-guided Framework for Multiplex Immunofluorescence Profiling of the NSCLC Tumor Microenvironment
Retrorectal Hamartoma Presenting as a Presacral Mass: Surgical Management and Diagnostic Challenges